Deficiency in SLC25A15, a hypoxia-responsive gene, promotes hepatocellular carcinoma by reprogramming glutamine...

Area of Science:

• Hepatocellular Carcinoma Research
• Cancer Metabolism
• Molecular Oncology

Background:

• The role of solute carrier family 25 member 15 (SLC25A15) in hepatocellular carcinoma (HCC) is not well understood.
• SLC25A15 is a key component of the urea cycle, essential for cellular metabolism.

Purpose of the Study:

• To investigate the impact of SLC25A15 on HCC progression.
• To elucidate the mechanisms by which SLC25A15 influences HCC development.
• To explore SLC25A15's role in glutamine metabolism reprogramming in HCC.

Main Methods:

• Large-scale data mining of HCC patient data.
• In vitro studies using HCC cell lines.
• In vivo studies using animal models.
• Organoid model development for HCC.
• Analysis of glutamine metabolism pathways.

Main Results:

• SLC25A15 expression is decreased in HCC tissues, correlating with poorer patient prognosis.
• Hypoxia reduces SLC25A15 expression in HCC, linked to HNF4A regulation.
• SLC25A15 deficiency upregulates SLC1A5, increasing glutamine uptake and promoting HCC progression via lipid synthesis.
• Low SLC25A15 leads to ammonia accumulation, suppressing OGDHL and reprogramming glutamine metabolism.
• Targeting glutamine metabolism enhances HCC cell sensitivity to anti-PD-L1 therapy.

Conclusions:

• SLC25A15 acts as a hypoxia-responsive tumor suppressor in HCC.
• SLC25A15 deficiency drives HCC progression by reprogramming glutamine metabolism through SLC1A5 and OGDHL.
• Targeting glutamine metabolism is a potential therapeutic strategy for SLC25A15-deficient HCC.
• SLC25A15 can serve as a biomarker for precision therapy and enhance anti-PD-L1 efficacy.